{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:45:49Z","timestamp":1789343149870,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41401-025-01481-2","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:05:11Z","timestamp":1739354711000},"page":"1733-1741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13\/STAT3 circuit"],"prefix":"10.1038","volume":"46","author":[{"given":"Jun-hao","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-pei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-ying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-liang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"1481_CR1","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.3390\/cancers13215350","volume":"13","author":"H Shaath","year":"2021","unstructured":"Shaath H, Elango R, Alajez NM. Molecular classification of breast cancer utilizing long non-coding RNA (lncRNA) Transcriptomes identifies novel diagnostic lncRNA panel for triple-negative breast cancer. Cancers. 2021;13:5350.","journal-title":"Cancers"},{"key":"1481_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116535","volume":"274","author":"PK Das","year":"2024","unstructured":"Das PK, Matada GSP, Pal R, Maji L, Dhiwar PS, Manjushree BV, et al. Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship. Eur J Med Chem. 2024;274:116535.","journal-title":"Eur J Med Chem"},{"key":"1481_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01869-8","volume":"26","author":"D Xiao","year":"2024","unstructured":"Xiao D, Zhang M, Qu Y, Su X. Functions of methyltransferase-like 3 in breast cancer: pathogenesis, drug resistance, and therapeutic target. Breast Cancer Res. 2024;26:110.","journal-title":"Breast Cancer Res"},{"key":"1481_CR4","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.csbj.2019.06.005","volume":"17","author":"S Lu","year":"2019","unstructured":"Lu S, Qian J, Guo M, Gu C, Yang Y. Insights into a crucial role of TRIP13 in human cancer. Comput Struct Biotechnol J. 2019;17:854\u201361.","journal-title":"Comput Struct Biotechnol J"},{"key":"1481_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-biochem-090920-103246","volume":"91","author":"Y Gu","year":"2022","unstructured":"Gu Y, Desai A, Corbett KD. Evolutionary dynamics and molecular mechanisms of HORMA domain protein signaling. Ann Rev Biochem. 2022;91:541\u201369.","journal-title":"Ann Rev Biochem"},{"key":"1481_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3892\/or.2023.8639","volume":"50","author":"L Zhao","year":"2023","unstructured":"Zhao L, Ye S, Jing S, Gao YJ, He T. Targeting TRIP13 for overcoming anticancer drug resistance (Review). Oncol Rep. 2023;50:202.","journal-title":"Oncol Rep"},{"key":"1481_CR7","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1111\/jcmm.17278","volume":"26","author":"J Lan","year":"2022","unstructured":"Lan J, Huang J, Tao X, Gao Y, Zhang L, Huang W, et al. Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways. J Cell Mol Med. 2022;26:2673\u201385.","journal-title":"J Cell Mol Med"},{"key":"1481_CR8","doi-asserted-by":"crossref","unstructured":"Sun YJ, Zhang Q, Cao SJ, Sun XH, Zhang JC, Zhang BY, et al. Tetrahydrocurcumin targets TRIP13 inhibiting the interaction of TRIP13\/USP7\/c-FLIP to mediate c-FLIP ubiquitination in triple-negative breast cancer. J Adv Res. 2024.S2090-1232(24)00496-X.","DOI":"10.1016\/j.jare.2024.11.004"},{"key":"1481_CR9","doi-asserted-by":"publisher","first-page":"300060521991019","DOI":"10.1177\/0300060521991019","volume":"49","author":"Z Chen","year":"2021","unstructured":"Chen Z, Wang X, Li X, Zhou Y, Chen K. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. J Int Med Res. 2021;49:300060521991019.","journal-title":"J Int Med Res"},{"key":"1481_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-019-0442-y","volume":"22","author":"CS Clairmont","year":"2020","unstructured":"Clairmont CS, Sarangi P, Ponnienselvan K, Galli LD, Csete I, Moreau L, et al. TRIP13 regulates DNA repair pathway choice through REV7 conformational change. Nat Cell Biol. 2020;22:87\u201396.","journal-title":"Nat Cell Biol"},{"key":"1481_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.04.024","volume":"11","author":"C Li","year":"2024","unstructured":"Li C, Pan D, Lin W, Deng D, Zhou Y, Zhao H, et al. RIOK1 synergizes with TRIP13 by regulating the E2F-Rb signaling pathway to promote the proliferation of esophageal cancer cells. Genes Dis. 2024;11:100990.","journal-title":"Genes Dis"},{"key":"1481_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1419072","volume":"11","author":"Y Li","year":"2024","unstructured":"Li Y, Jiang F, Zhu S, Jia H, Li C. STAT3 drives the malignant progression of low-grade gliomas through modulating the expression of STAT1, FOXO1, and MYC. Front Mol Biosci. 2024;11:1419072.","journal-title":"Front Mol Biosci"},{"key":"1481_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","volume":"38","author":"J-J Qin","year":"2019","unstructured":"Qin JJ, Yan L, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res. 2019;38:195.","journal-title":"J Exp Clin Cancer Res"},{"key":"1481_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216508","volume":"581","author":"S Wu","year":"2024","unstructured":"Wu S, Lu J, Zhu H, Wu F, Mo Y, Xie L, et al. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett. 2024;581:216508.","journal-title":"Cancer Lett"},{"key":"1481_CR15","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15961","volume":"12","author":"CD Bondi","year":"2024","unstructured":"Bondi CD, Hartman HL, Tan RJ. NRF2 in kidney physiology and disease. Physiol Rep. 2024;12:e15961.","journal-title":"Physiol Rep"},{"key":"1481_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4103\/1947-2714.100998","volume":"4","author":"T Mahmood","year":"2012","unstructured":"Mahmood T, Yang PC. Western blot: technique, theory, and trouble shooting. N Am J Med Sci. 2012;4:429\u201334.","journal-title":"N Am J Med Sci"},{"key":"1481_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-61779-080-5_20","volume":"731","author":"J van Meerloo","year":"2011","unstructured":"van Meerloo J, Kaspers GJL, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237\u201345.","journal-title":"Methods Mol Biol"},{"key":"1481_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1509","volume":"13","author":"Y He","year":"2023","unstructured":"He Y, Jiang S, Zhong Y, Wang X, Cui Y, Liang J, et al. USP7 promotes non-small-cell lung cancer cell glycolysis and survival by stabilizing and activating c-Abl. Clin Transl Med. 2023;13:e1509.","journal-title":"Clin Transl Med"},{"key":"1481_CR19","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1074\/jbc.M115.701979","volume":"291","author":"X Xu","year":"2016","unstructured":"Xu X, Han K, Tang X, Zeng Y, Lin X, Zhao Y, et al. The ring finger protein RNF6 induces leukemia cell proliferation as a direct target of pre-B-cell leukemia homeobox 1. J Biol Chem. 2016;291:9617\u201328.","journal-title":"J Biol Chem"},{"key":"1481_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41401-024-01366-w","volume":"46","author":"Z-Y Liu","year":"2025","unstructured":"Liu ZY, Zhang YW, Zhuang HX, Ou YJ, Jiang QY, Li PF, et al. Inhibiting the Otub1\/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer. Acta Pharmacol Sin. 2025;46:184\u201395.","journal-title":"Acta Pharmacol Sin"},{"key":"1481_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/cancers14020429","volume":"14","author":"SQ To","year":"2022","unstructured":"To SQ, Dmello RS, Richards AK, Ernst M, Chand AL. STAT3 signaling in breast cancer: multicellular actions and therapeutic potential. Cancers. 2022;14:429.","journal-title":"Cancers"},{"key":"1481_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04739-7","volume":"21","author":"Y Wang","year":"2023","unstructured":"Wang Y, Dong S, Hu K, Xu L, Feng Q, Li B, et al. The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway. J Transl Med. 2023;21:858.","journal-title":"J Transl Med"},{"key":"1481_CR23","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1002\/1878-0261.13201","volume":"16","author":"S Agarwal","year":"2022","unstructured":"Agarwal S, Afaq F, Bajpai P, Kim HG, Elkholy A, Behring M, et al. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4\/STAT3 axis and the Wnt\/\u03b2-catenin pathway in colorectal cancer. Mol Oncol. 2022;16:1728\u201345.","journal-title":"Mol Oncol"},{"key":"1481_CR24","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/0008-5472.CAN-18-3987","volume":"80","author":"Y Wang","year":"2020","unstructured":"Wang Y, Huang J, Li B, Xue H, Tricot G, Hu L, et al. A small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2020;80:536\u201348.","journal-title":"Cancer Res"},{"key":"1481_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jcis.2024.11.132","volume":"680","author":"D Sader","year":"2025","unstructured":"Sader D, Zlotver I, Moya S, Calabrese GC, Sosnik A. Doubly self-assembled dermatan sulfate\/chitosan nanoparticles for targeted siRNA delivery in cancer therapy. J Colloid Interface Sci. 2025;680:763\u201375.","journal-title":"J Colloid Interface Sci"},{"key":"1481_CR26","doi-asserted-by":"publisher","first-page":"e146893","DOI":"10.1172\/JCI146893","volume":"131","author":"C Li","year":"2021","unstructured":"Li C, Xia J, Franqui-Machin R, Chen F, He Y, Ashby TC, et al. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 2021;131:e146893.","journal-title":"J Clin Invest"},{"key":"1481_CR27","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.7150\/thno.92646","volume":"14","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhao H, Ren R, Zhou M, Zhang J, Wu Z, et al. GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. Theranostics. 2024;14:3470\u201385.","journal-title":"Theranostics"},{"key":"1481_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3892\/or.2021.8123","volume":"46","author":"R Lu","year":"2021","unstructured":"Lu R, Zhou Q, Ju L, Chen L, Wang F, Shao J. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway. Oncol Rep. 2021;46:172.","journal-title":"Oncol Rep"},{"key":"1481_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100951","volume":"47","author":"F Afaq","year":"2024","unstructured":"Afaq F, Agarwal S, Bajpai P, Diffalha SA, Kim HG, Peter S, et al. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. Neoplasia. 2024;47:100951.","journal-title":"Neoplasia"},{"key":"1481_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000529471","volume":"147","author":"P Ruggenenti","year":"2023","unstructured":"Ruggenenti P. The CARDINAL trial of bardoxolone methyl in Alport syndrome: when marketing interests prevail over patients clinical needs. Nephron. 2023;147:465\u20139.","journal-title":"Nephron"},{"key":"1481_CR31","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/tbj.13696","volume":"26","author":"G Oner","year":"2020","unstructured":"Oner G, Altintas S, Canturk Z, Tjalma W, Verhoeven Y, Van Berckelaer C, et al. Triple-negative breast cancer-role of immunology: a systemic review. Breast J. 2020;26:995\u20139.","journal-title":"Breast J"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01481-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01481-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01481-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T10:33:12Z","timestamp":1747909992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01481-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01481-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors have read the manuscript and agree to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}